Effect of Age and Lenvatinib Treatment on OS for Patients With Thyroid Cancer




CLICK HERE for the Hypothyroidism Revolution Program!
#thyroid #thyroiddiet #thyroidtreatment #thyroidtest

Lori J. Wirth, MD, hematology/oncology, Department of Medicine, Massachusetts General Hospital, discusses the SELECT trial, which examined the effect of age and lenvatinib treatment on overall survival (OS) for patients with 131I-refractory differentiated thyroid cancer.


Leave a Reply

Your email address will not be published. Required fields are marked *

*